The legal landscape for peptides in the United States is undergoing its biggest change in years. With HHS Secretary RFK Jr. announcing plans to reclassify 14 peptides from Category 2 to Category 1, the rules are shifting — but they haven't shifted yet. Here's where things actually stand.
Understanding the Legal Framework
There are three distinct ways peptides exist in the US market right now:
1. FDA-Approved Peptide Drugs These are peptides that went through the full FDA approval process and are available by prescription from regular pharmacies.
- •Semaglutide (Ozempic, Wegovy) — FDA-approved for diabetes and obesity
- •Tirzepatide (Mounjaro, Zepbound) — FDA-approved for diabetes and obesity
- •Bremelanotide / PT-141 (Vyleesi) — FDA-approved for HSDD in premenopausal women
These are fully legal with a prescription. Period.
2. Category 1 Peptides (Legal for Compounding) Category 1 means a licensed compounding pharmacy can prepare the peptide with a valid physician prescription. The compound itself is not FDA-approved, but the compounding process is legal under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Currently Category 1 (as of the September 2024 PCAC review): - AOD-9604 - CJC-1295 - Ipamorelin - Thymosin Alpha-1 - Selank
Expected to move to Category 1 (announced Feb 27, 2026 but not yet formally published): - BPC-157 - TB-500 (Thymosin Beta-4) - GHK-Cu - MOTS-C - Epitalon - KPV - Semax - Kisspeptin-10 - DSIP (Emideltide)
3. Category 2 Peptides (Restricted from Compounding) These peptides have been flagged by the FDA as having safety concerns. Licensed pharmacies cannot compound them.
Expected to REMAIN Category 2: - Melanotan II — cardiovascular and melanoma risks - GHRP-2 — adverse events including deaths reported - GHRP-6 — similar safety profile to GHRP-2 - Cathelicidin LL-37 — limited human safety data - PEG-MGF — insufficient clinical evidence
4. Grey Market "Research Chemicals" Peptides sold as "for research use only" by online vendors. These exist in a legal grey area:
- •Not FDA-approved for any use
- •Not scheduled or controlled substances (unlike steroids or narcotics)
- •Technically legal to sell for research purposes
- •Illegal to market for human consumption
- •Quality is unregulated — purity, potency, and sterility vary widely
The grey market is under increasing regulatory pressure. Peptide Sciences, the largest vendor, voluntarily shut down in March 2026. Seven major vendors have been flagged by Trustpilot as "not a good fit."
Compound-by-Compound Status
BPC-157 - **Current status:** Category 2 (restricted from compounding) - **Expected status:** Category 1 (pending formal FDA publication) - **FDA-approved:** No - **Grey market:** Available from research vendors (quality varies) - **Telehealth clinics:** Some clinics prescribe; availability will expand after reclassification
Semaglutide - **Current status:** FDA-approved (Ozempic, Wegovy) - **Compounding status:** Complex — FDA has challenged compounding of semaglutide due to patent and shortage issues - **Grey market:** Available from research vendors (illegal if marketed for human use) - **Telehealth clinics:** Widely available by prescription
TB-500 (Thymosin Beta-4) - **Current status:** Category 2 (restricted from compounding) - **Expected status:** Category 1 (pending formal FDA publication) - **FDA-approved:** No - **Grey market:** Available from research vendors - **Telehealth clinics:** Limited availability; expected to expand after reclassification
CJC-1295 - **Current status:** Removed from Category 2 in September 2024; under PCAC review - **FDA-approved:** No - **Grey market:** Available from research vendors - **Telehealth clinics:** Available from some clinics
Ipamorelin - **Current status:** Removed from Category 2 in September 2024; under PCAC review - **FDA-approved:** No - **Grey market:** Available from research vendors - **Telehealth clinics:** Available from some clinics
GHK-Cu - **Current status:** Category 2 (restricted from compounding) for injectable form - **Expected status:** Category 1 (pending formal FDA publication) - **FDA-approved:** No - **Topical forms:** Widely available in skincare products (not restricted) - **Telehealth clinics:** Limited availability currently
PT-141 (Bremelanotide) - **Current status:** FDA-approved as Vyleesi for HSDD in premenopausal women - **Compounding status:** May also be compounded for off-label use depending on classification - **Grey market:** Available from research vendors - **Telehealth clinics:** Available by prescription
Tirzepatide - **Current status:** FDA-approved (Mounjaro, Zepbound) - **Compounding status:** Similar legal complexity to semaglutide - **Grey market:** Available from research vendors - **Telehealth clinics:** Widely available by prescription
Selank - **Current status:** Removed from Category 2 in September 2024 - **FDA-approved:** No - **Grey market:** Available from research vendors - **Telehealth clinics:** Limited availability
Semax - **Current status:** Category 2 (restricted from compounding) - **Expected status:** Category 1 (pending formal FDA publication) - **FDA-approved:** No - **Grey market:** Available from research vendors
MK-677 (Ibutamoren) - **Current status:** Not a peptide (small molecule), not on the Category 2 list - **FDA-approved:** No - **Grey market:** Available from research vendors and some supplement sellers - **Legal status:** Unregulated as a research chemical; not a controlled substance
Melanotan II - **Current status:** Category 2 (restricted from compounding) - **Expected status:** Likely to REMAIN Category 2 - **Safety concerns:** Cardiovascular risks, association with melanoma, unpredictable side effects - **Grey market:** Available from research vendors (use carries significant risk)
Key Dates and Timeline
| Date | Event |
|---|---|
| September 2023 | FDA places ~17 peptides on Category 2 list |
| September 2024 | 5 peptides removed from Category 2 (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank) |
| October 2024 | PCAC reviews Ipamorelin |
| December 2024 | PCAC reviews CJC-1295, AOD-9604, Thymosin Alpha-1 |
| November 2025 | Rep. Diana Harshbarger sends letter to HHS requesting peptide reclassification |
| February 27, 2026 | HHS Secretary Kennedy announces intent to reclassify 14 peptides to Category 1 |
| March 2026 | Peptide Sciences voluntarily shuts down |
| March–April 2026 | Expected 30-day comment period |
| May–June 2026 | Expected FDA finalization of technical requirements |
| July 2026+ | State pharmacy boards expected to implement local rules |
What You Should Do Right Now
If you want legal, prescribed peptides: Contact a telehealth peptide clinic. Several peptides (CJC-1295, Ipamorelin, AOD-9604, Thymosin Alpha-1, Selank) are already available through compounding. The remaining 14 will follow once formal reclassification is published.
If you currently use research vendors: Understand the risks — quality is unregulated, legal status is grey, and the vendor landscape is shrinking. Consider transitioning to prescribed access as it becomes available.
If you're waiting for BPC-157 or TB-500: These are expected to become available through compounding pharmacies once the formal FDA reclassification is published (estimated mid-2026). Telehealth clinics will be the easiest access point.
This guide reflects information available as of March 7, 2026. Legal status is changing rapidly. This is not legal advice — consult a healthcare provider and/or attorney for guidance specific to your situation.